“Ongoing Patent Cliff, Failure of Next generation therapies and Fewer therapeutic Options likely to shift large number of patients towards Generics”, says RNCOS.
Noida, UP -- (SBWIRE) -- 08/04/2015 -- According to a new research report by RNCOS entitled, "US Generic Drug Market Outlook 2018", Obesity is one of the biggest challenges Americans have been facing over the years. The rate & prevalence of obesity has been rising in both children and adults. Sedentary lifestyles, In-take of more fast-food, incorporation of high fructose corn syrup products in food, lack of exercise and dependence on less physical based transportation are some of the root causes of soaring obesity rates. In particular, Grade 2 or higher obesity [a body mass index (BMI) of 35 or higher] significantly increases the risk of mortality.
Trust for America's Health and the Robert Wood Johnson Foundation projected that half of US adults will be obese by 2030 unless Americans change their ways. According to the Centre for Disease Control & Prevention prevalence of obesity will be raised approximately 44% by 2030 in adults as compared to 35% in 2013. Presently, the US market is facing patent expiries of number of lipid-regulators such as Lipitor, Zocor, and Mevacor etc, which will shift large number of patients towards Generic therapy. Moreover, Next-generation therapies in this class have generally failed to pass regulatory hurdles and few new branded products are expected in the near term. These facts support our estimation of growing Generics market under this segment in near future.
The report is spread in over 100 pages and provides an in-depth research and rational analysis of the current status and future prospect of the US Generics industry. The report provides clear picture of Generics market, its growth, and drivers & challenges. In addition to this, the study further highlights emerging trends and developments which have been occurring in the US over the years, market potential of Generics in key therapeutic segments, competitive landscape and regulatory scenario, among other pointers.
It also provides valuable information to pharmaceutical and generic drug companies and investors looking to enter in this market. Facts and figures regarding market size, growth, share, regulatory environment and trends in technology development have been thoroughly analyzed in the report to provide clients a comprehensive overview of the market.
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM731.htm
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm
About RNCOS
RNCOS is a leading industry research and consultancy firm incorporated in 2002. As a pioneer in syndicate market research, our vision is to be a global leader in the industry research space by providing research reports and actionable insights to companies across a range of industries such as Healthcare, IT and Telecom and Retail etc. We offer comprehensive industry research studies, bespoke research and consultancy services to Fortune 1000, Trade associations, and Government agencies worldwide.